%0 Journal Article
%T First and Best Treatments for EGFR and PD-L1 - Competition for First Line Therapy in Adenocarcinoma
%A Chong Bai
%A Chrisanthi Sardeli
%A Christoforos Kosmidis
%A George Papatsibas
%A Haidong Huang
%A Lonny Yarmus
%A Nikolaos Barbetakis
%A Paul Zarogoulidis
%A Theodora Kerenidi
%A Theodora Tsiouda
%A Wolfgang Hohenforst-Schmidt
%A Yan-Gao Man
%J Oncomedicine
%D 2017
%R 10.7150/oncm.20759
%X Lung cancer is still diagnosed at advanced stages since there are no blood markers or efficient prevention programs. Moreover, lack of early disease symptoms do lead patients for early diagnosis. In the past ten years novel targeted and non-targeted therapies have entered the market for advanced stage disease patients. Epidermal growth factor receptor and anaplastic lymphoma kinase agents are considered an excellent choice as first line treatment for adenocarcinoma. However; in the past few months PD-L1 >50% patients can be treated with immunotherapy as first line treatment. Moreover; second generation tyrosine kinase inhibitors are already on the market in the case of disease relapse in EGFR and ALK positive patients. In the current mini review we will focus on current up-to-date data regarding the best choice between tkis and immunotherapy as first line treatment for adenocarcinoma.
%K EGFR
%K ALK
%K PD-L1
%K Immunotherapy.
%U http://www.oncm.org/v02p0138.htm